DCF Advisers LLC Purchases Shares of 729,000 Corvus Pharmaceuticals, Inc. $CRVS

DCF Advisers LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 729,000 shares of the company’s stock, valued at approximately $5,613,000. Corvus Pharmaceuticals makes up approximately 1.5% of DCF Advisers LLC’s investment portfolio, making the stock its 16th biggest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Corvus Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock valued at $28,000 after buying an additional 748 shares in the last quarter. Quarry LP acquired a new position in Corvus Pharmaceuticals in the third quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new position in Corvus Pharmaceuticals in the third quarter valued at about $49,000. Fox Run Management L.L.C. acquired a new position in Corvus Pharmaceuticals in the fourth quarter valued at about $86,000. Finally, BNP Paribas Financial Markets boosted its position in Corvus Pharmaceuticals by 125.9% in the third quarter. BNP Paribas Financial Markets now owns 12,516 shares of the company’s stock valued at $92,000 after buying an additional 6,975 shares in the last quarter. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on CRVS shares. Weiss Ratings raised shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Friday, March 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 target price (up from $32.00) on shares of Corvus Pharmaceuticals in a research note on Friday, March 13th. The Goldman Sachs Group started coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS opened at $11.16 on Thursday. The stock has a market cap of $938.44 million, a P/E ratio of -21.46 and a beta of 0.84. The firm has a 50 day moving average price of $14.11 and a 200 day moving average price of $13.64. Corvus Pharmaceuticals, Inc. has a 52-week low of $3.55 and a 52-week high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Analysts predict that Corvus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.